TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39755168

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of a 21-day cycle
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 43
Study: 39755436

Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum
Number of subjects: 30
Study: 39755564

Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs)
Number of subjects: 820

Group type: COMPARATOR
Intervention: No BCTs (no-BCT condition)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: All four BCTs
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Unique combinations of BCTs (14 conditions)
Number of subjects: 820
Study: 39755573

Group type: EXPERIMENTAL
Intervention: FiO2 (fraction of inspired oxygen)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard oxygen therapy (control group)
Number of subjects: 200
Study: 39755576

Group type: EXPERIMENTAL
Intervention: Antenatal multiple micronutrient supplements (MMS) at varying doses up to ~75% of the tolerable upper intake level (UL)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo drink (control arm)
Number of subjects: 240
Study: 39755582

Group type: EXPERIMENTAL
Intervention: Fruquintinib plus sintilimab (F&S) in RT cohort
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fruquintinib plus sintilimab (F&S) in non-RT cohort
Number of subjects: 55
Study: 39755598

Group type: EXPERIMENTAL
Intervention: TCD pulsatility index guided norepinephrine titration
Number of subjects: 112

Group type: COMPARATOR
Intervention: SSC guidelines for MAP ≥ 65 mmHg
Number of subjects: 112
Study: 39755611

Group type: EXPERIMENTAL
Intervention: CAD/CAM milling of new maxillary dentures (Group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional relining method (Group B)
Number of subjects: 12
Study: 39755716

Group type: EXPERIMENTAL
Intervention: Breast cancer survivors (BCSs)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-cancer controls
Number of subjects: 140
Study: 39755925

Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR) 0.07 mg
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 495
Study: 39755971

Group type: EXPERIMENTAL
Intervention: 5 mg of hydrocodone with 300 mg of acetaminophen (opioid)
Number of subjects: 1815

Group type: COMPARATOR
Intervention: 400 mg of ibuprofen and 500 mg of acetaminophen (nonopioid)
Number of subjects: 1815
Study: 39756018

Group type: EXPERIMENTAL
Intervention: Weight loss intervention in the INKA trial
Number of subjects: 217

Group type: COMPARATOR
Intervention: Non-participation in the INKA trial (nINKA group)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Comparison of OKS between INKA and nINKA groups
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Secondary patient-reported outcomes in the INKA trial
Number of subjects: 217
Study: 39756156

Group type: EXPERIMENTAL
Intervention: TNG908
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 39756174

Group type: EXPERIMENTAL
Intervention: Get FIT + (intervention): personalized text messages with healthy lifestyle counselling, mHealth app (MyFitnessPal), and activity tracker.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Get FIT (control): healthy lifestyle counselling from a licensed health coach, mHealth app (MyFitnessPal), and activity tracker without personalized text messages.
Number of subjects: 54
Study: 39756216

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted influenza A(H7N9) inactivated vaccine (A(H7N9) IIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-year delayed boost with a heterologous adjuvanted A(H7N9) IIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant seasonal influenza vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heterologous A(H7N9) IIVs in the 2-dose priming series
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-HA stalk antibody responses
Number of subjects: 0
Study: 39756424

Group type: EXPERIMENTAL
Intervention: Vanzacaftor-tezacaftor-deutivacaftor
Number of subjects: 971

Group type: COMPARATOR
Intervention: Elexacaftor-tezacaftor-ivacaftor
Number of subjects: 971
Study: 39756425

Group type: EXPERIMENTAL
Intervention: Vanzacaftor-tezacaftor-deutivacaftor
Number of subjects: 78
Study: 39756444

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily
Number of subjects: 50
Study: 39756446

Group type: EXPERIMENTAL
Intervention: Brain radiotherapy combined with camrelizumab (200 mg intravenously once every 3 weeks) and platinum-doublet chemotherapy (pemetrexed 500 mg/m2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy
Number of subjects: 65
Study: 39756588

Group type: EXPERIMENTAL
Intervention: VR session (VRD group, n=178)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: VR session with hypnosis (VRH group, n=164)
Number of subjects: 342
Study: 39756673

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 352
Study: 39756693

Group type: EXPERIMENTAL
Intervention: NVX-CoV2601 plus PCV20 (combination group)
Number of subjects: 256

Group type: COMPARATOR
Intervention: NVX-CoV2601 plus placebo (NVX-only group)
Number of subjects: 256

Group type: COMPARATOR
Intervention: PCV20 plus placebo (PCV20-only group)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo plus placebo (placebo group)
Number of subjects: 256
Study: 39756819

Group type: EXPERIMENTAL
Intervention: Women (n=288)
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Men (n=889)
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 1177
Study: 39756820

Group type: EXPERIMENTAL
Intervention: Exposure to hypoxia (ascending from 760 m to 3100 m for a 2-day stay)
Number of subjects: 54
Study: 39756833

Group type: EXPERIMENTAL
Intervention: VLP Peanut
Number of subjects: 12
Study: 39756844

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 419
Study: 39757160

Group type: EXPERIMENTAL
Intervention: Electronic bidet
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sitz bath
Number of subjects: 75
Study: 39757186

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day) administered orally for 2 weeks followed by 1 week off in a 3-week cycle, in combination with continued use of EGFR-TKIs.
Number of subjects: 120
Study: 39757192

Group type: EXPERIMENTAL
Intervention: Urokinase (UK) 1,000,000 U
Number of subjects: 999

Group type: COMPARATOR
Intervention: Best medicine treatment (control)
Number of subjects: 999
Study: 39757368

Group type: EXPERIMENTAL
Intervention: Psychological risk assessment using PBSI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapist's risk assessment
Number of subjects: 0
Study: 39757748

Group type: EXPERIMENTAL
Intervention: Iberdomide (1.6 mg on days 1-21), ixazomib (3 mg on days 1, 8, 15), dexamethasone (20 mg on days 1, 8, 15, 22 for cycles 1-2; 10 mg on days 1, 8, 15, 22 for cycles 3-6)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Iberdomide, ixazomib and dexamethasone (I2D)
Number of subjects: 70
Study: 39757775

Group type: EXPERIMENTAL
Intervention: Measured resection method
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional 'two-finger' method
Number of subjects: 49
Study: 39757773

Group type: EXPERIMENTAL
Intervention: HES-I (Idiopathic Hypereosinophilia)
Number of subjects: 779
Study: 39757908

Group type: EXPERIMENTAL
Intervention: Motivational interview-based breastfeeding education (4 sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no motivational interview-based education)
Number of subjects: 76
Study: 39758009

Group type: EXPERIMENTAL
Intervention: Digital twin-predicted sites
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonpredicted sites
Number of subjects: 18
Study: 39758130

Group type: EXPERIMENTAL
Intervention: Deep learning model using baseline and 6-month FAF images
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Deep learning model using FAF images collected 6 months after baseline
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Deep learning model using FAF images collected at baseline and 6 months
Number of subjects: 597
Study: 39758223

Group type: EXPERIMENTAL
Intervention: Nutraceutical supplement (Clear Skin Formula; VitaMedica®) taken daily for 84 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsules taken daily for 84 days
Number of subjects: 40
Study: 39758508

Group type: COMPARATOR
Intervention: BP-lowering treatment
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Intensive glucose-lowering treatment
Number of subjects: 11140
Study: 39758592

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement (SQ-LNS) provided to mothers during pregnancy and 6 months postpartum and to their children from 6 to 18 months.
Number of subjects: 966

Group type: COMPARATOR
Intervention: Non-LNS group (control) receiving iron and folic acid or multiple micronutrients during pregnancy and postpartum.
Number of subjects: 966
Study: 39758693

Group type: EXPERIMENTAL
Intervention: Foam roller warm-up for three months plus one month follow-up without foam rolling
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group with general warm-up for four months
Number of subjects: 22
Study: 39758967

Group type: EXPERIMENTAL
Intervention: Encapsulated faecal microbiota transplantation (FMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 40
Study: 39759424

Group type: EXPERIMENTAL
Intervention: Iclepertin 10 mg + CCT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo + CCT
Number of subjects: 200
Study: 39759832

Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 47
Study: 39760061

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39760219

Group type: EXPERIMENTAL
Intervention: IBBIS II (integrated mental health care and vocational rehabilitation)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 900
Study: 39760239

Group type: EXPERIMENTAL
Intervention: Tape stripping combined with high-throughput RNA sequencing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tape stripping
Number of subjects: 66
Study: 39760302

Group type: EXPERIMENTAL
Intervention: 3-D acoustic radiation force impulse (ARFI) imaging for targeted prostate biopsy guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiparametric magnetic resonance imaging (mpMRI)-ultrasound fusion TP biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic sampling TP biopsy
Number of subjects: 0
Study: 39760815

Group type: EXPERIMENTAL
Intervention: AL2846 combined with gemcitabine (90 mg and 120 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: AL2846 combined with gemcitabine
Number of subjects: 33
Study: 39760981

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 47
Study: 39760983

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% applied twice daily for 4 weeks, then as needed up to 52 weeks
Number of subjects: 29
Study: 39761005

Group type: EXPERIMENTAL
Intervention: hSAP (12.5 μg/g)
Number of subjects: 0
Study: 39761016

Group type: EXPERIMENTAL
Intervention: Vaccinated group (107 infants)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Unvaccinated group (116 infants)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 223
Study: 39761063

Group type: EXPERIMENTAL
Intervention: TAK-071
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 39761213

Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39761305

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multicomponent Training (MT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Exercise Group
Number of subjects: 100
Study: 39761361

Group type: EXPERIMENTAL
Intervention: Machine learning-based pain assessment application
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nurses' pain assessment
Number of subjects: 68
Study: 39761483

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg once every 3 weeks
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 137
Study: 39761550

Group type: EXPERIMENTAL
Intervention: Mobile app for monitoring (AppO2) in addition to conventional monitoring
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional monitoring only
Number of subjects: 45
Study: 39761592

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (no amlodipine unless two BP ≥140/90 mmHg)
Number of subjects: 250
Study: 39761695

Group type: EXPERIMENTAL
Intervention: MPS IH (severe MPS I)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MPS IA (attenuated MPS I)
Number of subjects: 71

Group type: COMPARATOR
Intervention: MPS IH
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MPS IA
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MPS IH and MPS IA
Number of subjects: 71
Study: 39761745

Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2350

Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stent
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe tortuosity
Number of subjects: 2350
Study: 39761829

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 39762092

Group type: EXPERIMENTAL
Intervention: Patch ECG (ECG247 Smart Heart Sensor)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insertable cardiac monitor (Confirm Rx, Abbott)
Number of subjects: 14
Study: 39762097

Group type: EXPERIMENTAL
Intervention: Group-based self-management fall prevention intervention (eight 2-hour online synchronous sessions facilitated by a licensed healthcare professional)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (standard MS care and rehabilitation plus a brochure on fall risk factors and fall prevention)
Number of subjects: 240
Study: 39762098

Group type: EXPERIMENTAL
Intervention: 300 mg omalizumab administered subcutaneously every 4 weeks (Q4W) for 36 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 300 mg omalizumab administered subcutaneously every 6 weeks (Q6W) for 36 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood samples, Weekly Urticaria Activity Score, Chronic Urticaria Quality of Life Questionnaire, Dermatology Life Quality Index
Number of subjects: 0
Study: 39762099

Group type: EXPERIMENTAL
Intervention: hEDS group
Number of subjects: 282

Group type: COMPARATOR
Intervention: MFS group
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 282
Study: 39762105

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Number of subjects: 739
Study: 39762113

Group type: EXPERIMENTAL
Intervention: EIMG (Exercise is Medicine Greenville) intervention with a standardised instructional video and a 12-week evidence-informed physical activity programme.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EIMG onboard training for adopting clinics in Phase II.
Number of subjects: 20
Study: 39762111

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 39762123

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 76
Study: 39762160

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) conversations
Number of subjects: 29
Study: 39762230

Group type: EXPERIMENTAL
Intervention: DIAGNOdent pen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VistaCam iX
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visual-tactile method
Number of subjects: 20
Study: 39762248

Group type: EXPERIMENTAL
Intervention: AG-270/S095033 (oral, potent, reversible inhibitor of MAT2A) administered once daily (QD) or twice daily (BID) in 28-day cycles.
Number of subjects: 40
Study: 39762316

Group type: EXPERIMENTAL
Intervention: Hyfe CoughMonitor wrist-worn device
Number of subjects: 546
Study: 39762418

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group A)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group B)
Number of subjects: 186

Group type: COMPARATOR
Intervention: neoadjuvant chemoradiation alone (control group)
Number of subjects: 186
Study: 39762419

Group type: EXPERIMENTAL
Intervention: Glecirasib (JAB-21822) administered orally at 800 mg daily
Number of subjects: 0
Study: 39762421

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 33
Study: 39762422

Group type: EXPERIMENTAL
Intervention: Autogene cevumeran monotherapy
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Autogene cevumeran with atezolizumab
Number of subjects: 213
Study: 39762494

Group type: EXPERIMENTAL
Intervention: NELIP + FBBT
Number of subjects: 116

Group type: COMPARATOR
Intervention: NELIP
Number of subjects: 116
Study: 39762691

Group type: EXPERIMENTAL
Intervention: High levels of physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low levels of physical activity
Number of subjects: 0
Study: 39762740

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg orally disintegrating tablet
Number of subjects: 103
Study: 39762827

Group type: EXPERIMENTAL
Intervention: Electronic habit reminder (wristwatch with alarming sound)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Palatal crib
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Electronic habit reminder
Number of subjects: 22
Study: 39762831

Group type: EXPERIMENTAL
Intervention: Patients with lung cancer
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Caregivers of lung cancer patients
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Patients' illness perception
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Patients' mindfulness and self-compassion levels
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Caregivers' level of illness perception and number of other caregivers
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Caregivers' dyadic coping level, residence, and self-compassion level
Number of subjects: 254
Study: 39762850

Group type: EXPERIMENTAL
Intervention: Tooth-modified scan body (TMSB)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional scan body (CSB)
Number of subjects: 6
Study: 39762879

Group type: EXPERIMENTAL
Intervention: Lactic acid vaginal gel applied for 12 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral metronidazole 500 mg twice daily for seven days
Number of subjects: 32
Study: 39762887

Group type: EXPERIMENTAL
Intervention: Tailored nutrition intervention (EN and supplemental PN)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Tailored nutrition intervention
Number of subjects: 237
Study: 39762915

Group type: EXPERIMENTAL
Intervention: DV-U montage (cathode over T11/T12, anodes over umbilicus)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DV-I montage (cathode over T11/T12, anodes over iliac crests)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DV-PU montage (cathode over T11/T12, anodes over umbilicus)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DV-PI montage (dual paraspinal cathodes at T11/12, anodes over iliac crests)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DM-C montage (cathode over T11/12, anode 5 cm caudal)
Number of subjects: 15

Group type: COMPARATOR
Intervention: DM-R montage (cathode over T11/12, anode 5 cm rostral)
Number of subjects: 15
Study: 39762947

Group type: EXPERIMENTAL
Intervention: Subclinical depressive symptoms (DepS)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No subclinical depressive symptoms (NoDepS)
Number of subjects: 131
Study: 39762953

Group type: EXPERIMENTAL
Intervention: Overground robotic exoskeleton (ORE)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 149
Study: 39762954

Group type: EXPERIMENTAL
Intervention: Automatic segmentation using in-house software for vessel area and diameter extraction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 30
Study: 39762958

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I analysis using Siemens Healthineers Atellica VTLi
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Statistical analyses (random forest, logistic regression, gradient boosting)
Number of subjects: 2000
Study: 39762976

Group type: EXPERIMENTAL
Intervention: Text messaging-based intervention focused on HIV and STI prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic HIV education program promoting a healthy lifestyle
Number of subjects: 0
Study: 39762978

Group type: EXPERIMENTAL
Intervention: Robot-assisted kidney transplantation (RAKT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Open kidney transplantation (OKT)
Number of subjects: 106
Study: 39762986

Group type: EXPERIMENTAL
Intervention: PSG-assisted commencement of NIV settings
Number of subjects: 244

Group type: COMPARATOR
Intervention: Sham PSG
Number of subjects: 244
Study: 39763002

Group type: EXPERIMENTAL
Intervention: RS3 condition (Rural School Support Strategies)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic supports condition (standard trainings)
Number of subjects: 40
Study: 39763004

Group type: EXPERIMENTAL
Intervention: Archetype development methodology for primary care champions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Archetype development methodology for advance care planning facilitators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Archetype development methodology for patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synergy and challenges between archetypes
Number of subjects: 0